GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.62
-0.22 (-0.54%)
At close: 4:02PM EDT

40.62 0.00 (0.00%)
After hours: 5:38PM EDT

Stock chart is not supported by your current browser
Previous Close40.84
Open40.66
Bid40.62 x 100
Ask40.66 x 200
Day's Range40.58 - 40.85
52 Week Range37.20 - 44.54
Volume6,872,872
Avg. Volume3,333,709
Market Cap95.56B
Beta0.95
PE Ratio (TTM)40.38
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.99 (4.86%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Gilead (GILD) Poised for a Beat This Earnings Season?
    Zacks8 hours ago

    Is Gilead (GILD) Poised for a Beat This Earnings Season?

    A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.

  • GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
    Reuters14 hours ago

    GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

    GlaxoSmithKline (GSK.L) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.

  • Reuters14 hours ago

    GSK wins U.S. shingles vaccine approval, UK nod for gene therapy

    GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.

  • Reuters23 hours ago

    Britain backs GSK's gene therapy for 'bubble boy' syndrome

    Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.

  • FDA approves better vaccine against painful shingles virus
    Associated Press3 days ago

    FDA approves better vaccine against painful shingles virus

    U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.

  • Reuters3 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N). The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data. Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.

  • PR Newswire3 days ago

    Shingrix approved in the US for prevention of shingles in adults aged 50 and over

    Pooled clinical trial results showed 90 percent efficacy across all age groups LONDON , Oct. 20, 2017 /PRNewswire/ -- GlaxoSmithKline plc today announced that the US Food and Drug ...

  • Reuters3 days ago

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co. The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data.

  • Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
    Zacks3 days ago

    Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool3 days ago

    3 High-Yield Pharmaceutical Stocks

    High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

  • China Biotech Promise Struggles to Keep Foreign Innovators
    Bloomberg4 days ago

    China Biotech Promise Struggles to Keep Foreign Innovators

    As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.

  • Novartis Reports Positive Results on Thrombocytopenia Drug
    Zacks4 days ago

    Novartis Reports Positive Results on Thrombocytopenia Drug

    Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks5 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Market Realist5 days ago

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks7 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks10 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Reuters10 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • CNBC11 days ago

    Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn

    Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.

  • The Wall Street Journal12 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • May to consult business leaders on Brexit
    Reuters15 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • 3 High-Yield Healthcare Stocks
    Motley Fool15 days ago

    3 High-Yield Healthcare Stocks

    If you're on the hunt for above-average yields, these three healthcare stocks should be on your radar.

  • Market Realist18 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Market Realist18 days ago

    Performance of GlaxoSmithKline’s Consumer Healthcare Segment

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.

  • Market Realist18 days ago

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.